Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119232) titled 'The Effect of GLP-1 Receptor Agonist on GLP-1/cAMP/VEGF, SDF-1/CRCX4 Pathways and the Mechanism of Neovascularization in Type 2 diabetes Angiopathy' on Feb. 24.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The First Affiliated Hospital of Chengdu Medical College
Condition:
Type 2 diabetes mellitus and its vascular complications
Intervention:
Experimental group:Dulaglutide (0.75mg - 1.5mg once a week, subcutaneous injection)
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-04-01
Target Sample Size: Experimental group:24;Control group:24;
Coun...